Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HH102
- Development stage
- Preclinical
- Lead developer
- Hedgehog Co.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
HH102 is a monoclonal antibody targeting the Eph receptor B3 (EPHB3), currently under development by Hedgehog Technology for the treatment of solid cancers. EPHB3 is a receptor tyrosine kinase involved in cell-cell communication and signaling pathways that are often dysregulated in various malignancies. HH102 functions by competitively inhibiting the interaction between the EPHB3 receptor and its ephrin ligands, thereby modulating Eph receptor signaling to suppress tumor growth and progression. As of early 2024, the drug is in the discovery/hit stage of preclinical development.
Beyond the preview
Go deeper on HH102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HH102.